Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Maurizio Fava, M.D.

Co-Author

This page shows the publications co-authored by Maurizio Fava and Timothy Petersen.
Connection Strength

5.529
  1. Petersen T, Perlis RH, Ticknor C, Lohr J, Solvason HB, O'Reardon JP, Wohlreich MM, Andreotti C, Wilson M, Fava M. Efficacy of duloxetine for the treatment of depression: relationship to most recent antidepressant trial. Psychopharmacol Bull. 2008; 41(1):34-45.
    View in: PubMed
    Score: 0.412
  2. Petersen T, Iosifescu DV, Papakostas GI, Shear DL, Fava M. Clinical characteristics of depressed patients with comorbid diabetes mellitus. Int Clin Psychopharmacol. 2006 Jan; 21(1):43-7.
    View in: PubMed
    Score: 0.359
  3. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005 Aug; 25(4):336-41.
    View in: PubMed
    Score: 0.348
  4. Petersen TJ, Alpert JE, Papakostas GI, Bernstein EM, Freed R, Smith MM, Fava M. Early-onset depression and the emotional and behavioral characteristics of offspring. Depress Anxiety. 2003; 18(2):104-8.
    View in: PubMed
    Score: 0.291
  5. Petersen T, Dording C, Neault NB, Kornbluh R, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan; 26(1):177-87.
    View in: PubMed
    Score: 0.272
  6. Targum SD, Burch DJ, Asgharnejad M, Petersen T, Gomeni R, Fava M. Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients. Eur Neuropsychopharmacol. 2014 Aug; 24(8):1188-95.
    View in: PubMed
    Score: 0.161
  7. Farabaugh A, Bitran S, Nyer M, Holt DJ, Pedrelli P, Shyu I, Hollon SD, Zisook S, Baer L, Busse W, Petersen TJ, Pender M, Tucker DD, Fava M. Depression and suicidal ideation in college students. Psychopathology. 2012; 45(4):228-34.
    View in: PubMed
    Score: 0.140
  8. Pedrelli P, Farabaugh AH, Zisook S, Tucker D, Rooney K, Katz J, Clain AJ, Petersen TJ, Fava M. Gender, depressive symptoms and patterns of alcohol use among college students. Psychopathology. 2011; 44(1):27-33.
    View in: PubMed
    Score: 0.125
  9. Guidi J, Pender M, Hollon SD, Zisook S, Schwartz FH, Pedrelli P, Farabaugh A, Fava M, Petersen TJ. The prevalence of compulsive eating and exercise among college students: an exploratory study. Psychiatry Res. 2009 Jan 30; 165(1-2):154-62.
    View in: PubMed
    Score: 0.110
  10. Pedrelli P, Feldman GC, Vorono S, Fava M, Petersen T. Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression. Psychiatry Res. 2008 Dec 15; 161(3):302-8.
    View in: PubMed
    Score: 0.109
  11. Petersen T, Fava M, Alpert JE, Vorono S, Sanders KM, Mischoulon D. Does psychiatry residency training reflect the "real world" of psychiatry practice? A survey of residency graduates. Acad Psychiatry. 2007 Jul-Aug; 31(4):281-9.
    View in: PubMed
    Score: 0.099
  12. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani GK, Spencer DC, Petersen T, Klinkman M, Warden D, Nicholas L, Fava M. Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. Ann Fam Med. 2007 Mar-Apr; 5(2):126-34.
    View in: PubMed
    Score: 0.097
  13. Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. Ann Clin Psychiatry. 2007 Jan-Mar; 19(1):5-8.
    View in: PubMed
    Score: 0.096
  14. Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 2007 Jan 15; 149(1-3):195-200.
    View in: PubMed
    Score: 0.096
  15. Papakostas GI, Miller KK, Petersen T, Sklarsky KG, Hilliker SE, Klibanski A, Fava M. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun; 67(6):952-7.
    View in: PubMed
    Score: 0.092
  16. Papakostas GI, Petersen TJ, Perlis RH, Judy AE, Burns AM, Alpert JE, Birnbaum RJ, Fava M. A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2006 Apr; 26(2):216-8.
    View in: PubMed
    Score: 0.091
  17. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006 Feb; 26(1):56-60.
    View in: PubMed
    Score: 0.090
  18. Harley R, Petersen T, Scalia M, Papakostas GI, Farabaugh A, Fava M. Problem-solving ability and comorbid personality disorders in depressed outpatients. Depress Anxiety. 2006; 23(8):496-501.
    View in: PubMed
    Score: 0.090
  19. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, Nierenberg AA, Fava M. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005 Sep-Oct; 67(5):703-6.
    View in: PubMed
    Score: 0.088
  20. Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res. 2006 Jun; 40(4):370-3.
    View in: PubMed
    Score: 0.086
  21. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Alpert JE, Rosenbaum JF, Fava M. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8.
    View in: PubMed
    Score: 0.086
  22. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec; 24(6):661-4.
    View in: PubMed
    Score: 0.083
  23. Papakostas GI, Petersen T, Denninger JW, Tossani E, Pava JA, Alpert JE, Nierenberg AA, Fava M. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol. 2004 Oct; 24(5):507-11.
    View in: PubMed
    Score: 0.082
  24. Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE, Rosenbaum JF, Fava M. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):59-63.
    View in: PubMed
    Score: 0.082
  25. Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5.
    View in: PubMed
    Score: 0.081
  26. Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8.
    View in: PubMed
    Score: 0.081
  27. Papakostas GI, Iosifescu DV, Petersen T, Hamill SK, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. J Clin Psychopharmacol. 2004 Aug; 24(4):467-9.
    View in: PubMed
    Score: 0.081
  28. Petersen T, Papakostas GI, Mahal Y, Guyker WM, Beaumont EC, Alpert JE, Fava M, Nierenberg AA. Psychosocial functioning in patients with treatment resistant depression. Eur Psychiatry. 2004 Jun; 19(4):196-201.
    View in: PubMed
    Score: 0.080
  29. Papakostas GI, Petersen T, Hughes ME, Nierenberg AA, Alpert JE, Fava M. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res. 2004 May 30; 126(3):287-90.
    View in: PubMed
    Score: 0.080
  30. Petersen T, Harley R, Papakostas GI, Montoya HD, Fava M, Alpert JE. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine. Psychol Med. 2004 Apr; 34(3):555-61.
    View in: PubMed
    Score: 0.079
  31. Papakostas GI, Petersen TJ, Iosifescu DV, Summergrad P, Sklarsky KG, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. J Clin Psychiatry. 2004 Apr; 65(4):543-6.
    View in: PubMed
    Score: 0.079
  32. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004 Feb; 65(2):217-21.
    View in: PubMed
    Score: 0.078
  33. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):13-7.
    View in: PubMed
    Score: 0.078
  34. Papakostas GI, Petersen T, Denninger JW, Montoya HD, Nierenberg AA, Alpert JE, Fava M. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Ann Clin Psychiatry. 2003 Sep-Dec; 15(3-4):187-92.
    View in: PubMed
    Score: 0.076
  35. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45.
    View in: PubMed
    Score: 0.075
  36. Papakostas GI, Petersen T, Denninger J, Sonawalla SB, Mahal Y, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms in treatment-resistant depression. Psychiatry Res. 2003 May 01; 118(1):39-45.
    View in: PubMed
    Score: 0.074
  37. Alpert JE, Petersen T, Roffi PA, Papakostas GI, Freed R, Smith MM, Spector AR, Nierenberg AA, Rosenbaum JF, Fava M. Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. Psychother Psychosom. 2003 Mar-Apr; 72(2):102-6.
    View in: PubMed
    Score: 0.074
  38. Fava M, Papakostas GI, Petersen T, Mahal Y, Quitkin F, Stewart J, McGrath P. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003 Mar; 15(1):17-22.
    View in: PubMed
    Score: 0.074
  39. Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, Worthington JJ, Tedlow J, Alpert JE, Fava M. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003 Feb; 23(1):92-5.
    View in: PubMed
    Score: 0.073
  40. Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003 Jan; 64(1):35-9.
    View in: PubMed
    Score: 0.073
  41. Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, Nierenberg AA, Rosenbaum JE, Fava M. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002 Sep; 14(3):143-7.
    View in: PubMed
    Score: 0.071
  42. Petersen T, Hughes M, Papakostas GI, Kant A, Fava M, Rosenbaum JF, Nierenberg AA. Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom. 2002 Sep-Oct; 71(5):269-74.
    View in: PubMed
    Score: 0.071
  43. Sonawalla SB, Papakostas GI, Petersen TJ, Yeung AS, Smith MM, Sickinger AH, Gordon J, Israel JA, Tedlow JR, Lamon-Fava S, Fava M. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics. 2002 Jul-Aug; 43(4):310-6.
    View in: PubMed
    Score: 0.070
  44. Nierenberg AA, Phillips KA, Petersen TJ, Kelly KE, Alpert JE, Worthington JJ, Tedlow JR, Rosenbaum JF, Fava M. Body dysmorphic disorder in outpatients with major depression. J Affect Disord. 2002 May; 69(1-3):141-8.
    View in: PubMed
    Score: 0.069
  45. Petersen T, Papakostas GI, Bottonari K, Iacoviello B, Alpert JE, Fava M, Nierenberg AA. NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiatry Res. 2002 Jan 31; 109(1):9-16.
    View in: PubMed
    Score: 0.068
  46. Petersen T, Bottonari K, Alpert JE, Fava M, Nierenberg AA. Use of the five-factory inventory in characterizing patients with major depressive disorder. Compr Psychiatry. 2001 Nov-Dec; 42(6):488-93.
    View in: PubMed
    Score: 0.067
  47. Petersen T, Gordon JA, Kant A, Fava M, Rosenbaum JF, Nierenberg AA. Treatment resistant depression and axis I co-morbidity. Psychol Med. 2001 Oct; 31(7):1223-9.
    View in: PubMed
    Score: 0.067
  48. Kornbluh R, Papakostas GI, Petersen T, Neault NB, Nierenberg AA, Rosenbaum JF, Fava M. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull. 2001; 35(3):150-6.
    View in: PubMed
    Score: 0.063
  49. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Oct; 66(10):1326-30.
    View in: PubMed
    Score: 0.022
  50. Papakostas GI, Petersen TJ, Green C, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M, Posternak MA. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry. 2005 Jul-Sep; 17(3):161-5.
    View in: PubMed
    Score: 0.022
  51. Farabaugh A, Fava M, Mischoulon D, Sklarsky K, Petersen T, Alpert J. Relationships between major depressive disorder and comorbid anxiety and personality disorders. Compr Psychiatry. 2005 Jul-Aug; 46(4):266-71.
    View in: PubMed
    Score: 0.022
  52. Papakostas GI, Petersen TJ, Farabaugh AH, Murakami JL, Pava JA, Alpert JE, Fava M, Nierenberg AA. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. J Clin Psychiatry. 2003 Nov; 64(11):1357-61.
    View in: PubMed
    Score: 0.019
  53. Papakostas GI, Petersen T, Worthington JJ, Roffi PA, Alpert JE, Fava M, Nierenberg AA. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int Clin Psychopharmacol. 2003 Sep; 18(5):293-6.
    View in: PubMed
    Score: 0.019
  54. Papakostas GI, Petersen T, Iosifescu DV, Roffi PA, Alpert JE, Rosenbaum JF, Fava M, Nierenberg AA. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):183-8.
    View in: PubMed
    Score: 0.019
  55. Papakostas GI, Petersen T, Sonawalla SB, Merens W, Iosifescu DV, Alpert JE, Fava M, Nierenberg AA. Serum cholesterol in treatment-resistant depression. Neuropsychobiology. 2003; 47(3):146-51.
    View in: PubMed
    Score: 0.018
  56. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Spector AR, Alpert JE, Fava M, Nierenberg AA. Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiatry. 2003 Jan-Feb; 44(1):44-50.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.